Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomibuvir and Telaprevir Combination in Genotype 1 HCV
NCT01080222Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of lomibuvir in hepatitis C (HCV) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and Tolerability at 40 weeks. Started Aug 2010; status: terminated.
02
Drugs
lomibuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01080222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01080222.